Results 141 to 150 of about 13,772,328 (296)

Human leukocyte antigen genotype modulates cytomegalovirus- and Epstein-Barr virus-specific T-cell response in healthy donors for optimized virus-specific T-cell donor selection. [PDF]

Front Immunol
Mora-Buch R, Pasamar H, Tomás-Marín M, Enrich E, Andrés-Rozas M, Peña-Gómez C, García Bosca M, Rudilla F.   +7 more
europepmc   +1 more source

Expression and immmunogenicity of HLA-B27 in high-transfection recipient P815: [PDF]

, 1989
Wildner, G., Kuon, W., Thureau, S. R., Weiss, Elisabeth H., Riethmüller, Gert   +4 more
core   +1 more source

Allogeneic Hematopoietic Stem Cell Transplant recipients in Spain: Human Leucocyte Antigen characteristics and diversity by high-resolution analysis

There are many studies on the polymorphism of the HLA system in healthy donor populations, such as registries of unrelated bone marrow donors. Investigations on the characterization of the HLA complex in hematopoietic stem cell transplant (HSCT) patients,
Solano Vercet, Carlos, Planelles Silvestre, Dolores, Piñana, José Luis, Guerreiro, Manuel   +3 more
core   +1 more source

Targeting Amastigote and Trypomastigote Phases: Multi‐Epitope Vaccine Strategy Against Trypanosoma cruzi

Biotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Effective vaccines against Trypanosoma cruzi, the causative agent of Chagas disease, are urgently needed. Here, we report the design and in silico validation of a novel multiepitope vaccine construct targeting the key surface proteins ASP‐2 and gp82. Using a comprehensive immunoinformatics pipeline, we identified and selected 38 potent T‐cell (
Maria Karolaynne da Silva, Caio Patrício de Souza Sena, Davi Serradella Vieira, Magdi E. A. Zaki, Leow Chiuan Yee, Shahina Akter, Umberto Laino Fulco, Jonas Ivan Nobre Oliveira, João Firmino Rodrigues‐Neto   +8 more
wiley   +1 more source

Antibodies to Non-HLA Antigens and Their Role in Organ Transplant Rejection. [PDF]

Int J Immunogenet
Jaklová K, Vychytilová K, Glosová A, Slavcev A.   +3 more
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

T-cell receptor repertoires against HLA class I-restricted minor histocompatibility antigens are highly diverse with a small subset of public clonotypes. [PDF]

J Immunother Cancer
Fuchs KJ, van de Meent M, Kester MGD, Hagedoorn RS, Khatri I, van Balen P, Heemskerk MHM, van den Akker EB, Falkenburg JHF, Griffioen M.   +9 more
europepmc   +1 more source

Precision medicine in paediatrics: Progress and priorities

British Journal of Clinical Pharmacology, EarlyView.
Precision medicine is revolutionizing personalized healthcare, advancing both diagnostics and therapeutics at an unprecedented pace. Reviewing the paediatric applications of pharmacometrics, pharmacogenomics and advanced therapy medicinal products highlights not only the relevance of these exciting innovations to frontline care but also the significant
Nicola Husain, Claire Booth, Joseph F. Standing, Charlotte I. S. Barker   +3 more
wiley   +1 more source

The evolution of cellular therapies in sarcoma: Breakthroughs, challenges, and future directions. [PDF]

Hum Vaccin Immunother
Wannaphut C, Thirasastr P, Livingston J, Araujo D, Conley A, Keung E, Roland C, Somaiah N.   +7 more
europepmc   +1 more source

Cell and Gene Therapies Manufacturing Challenges and Integrated Good Manufacturing Practices Solutions: A Lifecycle Perspective

Biotechnology and Bioengineering, EarlyView.
Lifecycle perspective on cell and gene therapy manufacturing challenges and enabling GMP solutions. ABSTRACT Cell and gene therapies (CGTs) are revolutionizing modern medicine; however, making these advanced medicines scalable and readily available to commercial manufacturers worldwide is a major challenge. The number of approved CGT products continues
Rajath Samaga, Udisha Singh, Sachin Dattram Pawar   +2 more
wiley   +1 more source